Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Sitting at a market capitalization of $159 billion, Amgen (AMGN) is a biotech powerhouse. Founded in 1980, it is one of the biggest names in the healthcare and biotech industry, with a strong history ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...

Rights Mar 23, 2010 Mar 25, 2010 Oct 30, 2009 Rights ratio: 1 share for every 16 held at a price of Rs 475.0 Bonus Dec 10, 2009 Dec 11, 2009 Oct 30, 2009 Bonus Ratio: 1 share(s) for every 1 shares ...

Rights Aug 28, 1995 Sep 20, 1995 Aug 24, 1995 Rights ratio: 1 share for every 1 held at a price of Rs 45.0 Rights Jan 28, 1994 Feb 22, 1994 Jan 27, 1994 Rights ratio: 1 share for every 1 held at a ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...